Loading...
NPI 1508105024 · Seattle, WA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Adaptive Biotechnologies Corporation is a clinical medical laboratory provider located in Seattle, Washington. This profile covers 1 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Adaptive Biotechnologies Corporation |
| Address | 1165 Eastlake Ave E |
| City | Seattle |
| State | WA |
| ZIP | 98109 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 4, 2013 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $21.9M |
| Medicaid | $1.1M |
ADAPTIVE BIOTECHNOLOGIES CORPORATION presents as a clinical molecular laboratory whose Medicare activity is concentrated entirely in molecular pathology coding: 81479 (a catch‑all molecular pathology code) accounts for 100.0% of this provider's total Medicare revenue, which totals $21.9M. The Medicare reporting pattern and the code description indicate the operation focuses on high-complexity molecular testing rather than broad, diverse procedural lines.
On the Medicaid side the provider also concentrates on molecular pathology and a proprietary PLA: 81479 generates $959.1K across 5.5K claims (88.0% of the provider's total Medicaid revenue) and 0364U generates $130.2K across 576 claims (12.0% of Medicaid revenue), together accounting for 100.0% of its Medicaid revenue of $1.1M. These counts and average paid/claim figures ($173 avg for 81479 and $226 avg for 0364U) point to routine repeat testing activity plus a measurable contribution from a branded assay.
The payer mix is heavily Medicare‑weighted: total Medicare revenue is $21.9M compared with $1.1M in Medicaid, making this organization effectively Medicare‑dominated in scale while maintaining a small but concentrated Medicaid footprint. That imbalance suggests commercial/governmental contracting and revenue risk will be driven primarily by Medicare pricing and utilization trends for molecular pathology.
Competitive standing for 81479 differs by payer: nationally on Medicare the provider’s 81479 activity ranks #10 of 80 providers (89th percentile) but is described as a "typical, unremarkable volume for this code," indicating an above‑median national presence without being an extreme outlier. In contrast, the same code on Medicaid ranks #1 of 7 providers in‑state (100th percentile; notably above typical state volume), signaling a dominant in‑state position for non‑specific molecular pathology billing.
0364U is a Proprietary Laboratory Analyses (PLA) code specific to the clonoSEQ® Assay; the reported Medicaid activity (576 claims, $130.2K revenue) is assigned to this provider and it ranks #1 of 1 providers in‑state (0th percentile; no state peer volume comparison available). That combination indicates the lab is the sole in‑state reporter for this PLA in the dataset, consistent with offering a branded MRD monitoring assay alongside broader molecular pathology services.
Revenue concentration is extreme by design: precomputed measures show the top 3 Medicare codes account for 100.0% of Medicare revenue and the top 3 Medicaid codes account for 100.0% of Medicaid revenue. This concentration emphasizes dependence on a narrow set of molecular pathology and PLA services for both payers and a limited product mix driving most billing.
The coding and payment pattern (high average paid/claim on Medicare for 81479 at $6,733 avg paid/claim across 3.3K claims, and much lower Medicaid averages for the same code) reflect payer differences in unit payment and likely case mix or billing modality between Medicare and Medicaid. These contrasts underline that the provider’s revenue exposure is sensitive not only to volume of molecular testing but also to payer‑specific reimbursement levels.
The provider has an established NPI tenure (enumerated 2013-02-04, ~13 years ago), supporting that this concentrated service mix and the observed Medicare scale are the result of sustained operations rather than a short‑term reporting artifact. Given the longevity and narrow code base, analysts should treat changes in utilization or reimbursement for 81479 and 0364U as high‑leverage events for this entity’s future revenue trajectories.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 3,260 | $6,730 | $21.9M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81479 | 1 | 10 | 90 | $5,800 | $3.7M |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 5,540 | $170 | $959.1K |
| 0364U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0364U only for… | 580 | $230 | $130.2K |
How this provider's Medicaid billing volume and revenue compare to other Washington providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Washington median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 1 | 10 | 190 | $130 | $160K |
| 0364U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0364U only for… | 1 | 10 | 580 | $230 | $130.1K |
Other providers in the same ZIP code as Adaptive Biotechnologies Corporation, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Fred Hutchinson Cancer Center | WA | General Acute Care Hospital | $0 | $72.6M |
| Emily Program PC | WA | Community/Behavioral Health Agency | $0 | $5.4M |
| Zhihong Zhang | WA | Hematology & Oncology Physician | $1.1M | $0 |
| Manh Pham | WA | Family Nurse Practitioner | $211.9K | $0 |
| Jonathan Chen | WA | Radiation Oncology Physician | $189.1K | $0 |
| Heather Rogers | WA | Dermatology Physician | $186.8K | $0 |
| Lauren East | WA | Diagnostic Radiology Physician | $106K | $78.1K |
| Emily Weg | WA | Radiation Oncology Physician | $165.4K | $0 |
| Mark Wagner | WA | Sports Medicine (Family Medicine) Physician | $138.4K | $0 |
| Uma Malhotra | WA | Infectious Disease Physician | $114K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.